source
- Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer winGermany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.
- Siemens Healthineers teams with Paradromics to develop multimodal imaging platform for brain-computer interfacesSiemens Healthineers and Paradromics announced a collaboration to build an advanced multimodal imaging system designed to support implantable brain‑computer interfaces (BCIs). The partnership combi…